Weight gain as a predictor of long term clozapine efficacy

Clinical Drug Investigation

Volumn 12, Issue 1, 1996, Pages 16-25

  Jalenques, Isabelle ^a   Tauveron, Igor ^a   Albuisson, Eliane ^b   Audy, Veronique ^a   Fleury Duhamel, Nathalie ^b   Coudert, André Julien ^a  

^a Hopital Saint Jacques Clermont Ferrand   (France)

^b ONERA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; ONSET AGE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0029761983     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199612010-00003     Document Type: Article

References (40)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
2. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329-38
3. Naher D, Hippius H. The European experience with clozapine. Hosp Community Psychiatry 1990; 41: 886-90
4. Povlsen UJ, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine tor up to 12 years. Acta Psychiatr Scand 1985; 71: 176-85
5. Hemphill RE, Pascoe DF, Zabow T. An investigation of clozapine in the treatment of acute and chronic schizophrenia and gross behavior disorders. S Afr Med J 1975; 49: 2121-5
6. Simpson GM, Varga E. Clozapine. A new and unusual antipsychotic agent. Psychopharmacol Bull 1975; 11: 14-5
7. Nair NPV, Zicherman V, Schwartz G. Dopamine and schizophrenia: a reappraisal in the light of clinical studies with clozapine. Can Psychiatr Assoc J 1977; 22: 285-93
8. Carson WH, Forbes RA. Clozapine-induced weight gain [letter]. Am J Psychiatry 1990; 147: 1694
9. Cohen S, Chiles J, MacNaughton A. Weight gain associated with clozapine. Am J Psychiatry 1990; 147: 503-4
10. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746-53
11. Lamberti JS, Bellnier T, Schwarzkopf SB. Long-term course of clozapine-induced weight gain. Schizophr Res 1993; 9: 277-8
12. Leadhetter R, Shutty M, Pavalonis D, er al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68-70
13. Overall JK, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812
14. May PRA, Dencker SJ, Hubbard JW, et al. A systematic approach to treatment resistance in schizophrenic disorder. In: Dencker SJ, Kulhanerk F, editors. Treatment resistance in schizophrenia. Braunschweig: Friedr. Vieweg & Sohn Verlgsgesellschaft mbh 1988: 22-33
15. Opler LA, Kay SR, Lindmayer JP, et al. Entretien structuré clinique pour l'éclielle de syndrome positif et négatif (PANSS) (SCI-PANSS). Multihealth Systems Inc; Traduction française Jean Pierre Lindmayer 1987
16. Dagnelie P. Théories et méthodes statistiques. Gembloux, Les Presses Agronomiques de Gembloux 1973; 2ème éd. Vol 1. 1973
17. Gailliez F, Pages JP. Introduction à l'analyse des données. Société de Mathématiques Appliquées et de Sciences Humaines, Paris 1976
18. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 1989; 99 Suppl.: 68S-72S
19. Jalenques I, Coudert AJ. Une nouvelle approche médicamenteuse des schizophrénies résistantes: la clozapine. Etude prospective à long terme chez 16 patients. Acta Psychiatr Belg 1992; 92: 323-38
20. Davis JM, Schaffer GB, Killian GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6: 70-87
21. Marder SR, Ames D, Wirshing WC, et al. Schizophrenia. Psychiatr Clin North Am 1993; 16 (3): 567-87
22. Jalenques I. Drug-resistant schizophrenia. CNS Drugs 1996; 5 (1): 8-23
23. Mefferd RB, Labrosse EH, Gawienowski AM, et al. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. J Ner Ment Dis 1958; 127: 167-79
24. Planansky K. Changes in weight in patients receiving a 'tranquilizing' drug. Psychiatr Q 1958; 32: 289-303
25. Klett GJ, Caffey EM. Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry 1960; 2: 102-8
26. Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenazine, and clopenthixol. Dan Med Bull 1964; 11: 182-9
27. Holden JMC, Holden UP. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics 1970; 9: 551-61
28. Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979; 40: 528-30
29. Brady KT. Weight gain associated with psychotropic drugs. S Med J 1989; 82: 611-7
30. Johnson DA, Breen M. Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand 1979; 59: 525-8
31. Marriott P, Pansa M, Heip A. Depot fluphenazine maintenance treatment and associated weight changes. Compr Psychiatry 1981; 22: 320-5
32. Goodall E, Oxtoby C, Richards R, et al. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988; 153: 208-13
33. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214-7
34. Wiebe AJ. Weight gain with clozapine treatment [letter]. Can J Psychiatry 1993; 38: 70
35. Gudelsky GA, Nash JF, Koenig JI, et al. Neuroendocrine effects of typical and atypical antipsychotics in the rat. Psychopharmacol Bull 1987; 23: 482-6
36. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Bed) 1989; 99 Suppl.: 18S-27S
37. Meltzer HY, Gudelsky GA. Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. Arzneimittel Forschung 1992; 42: 268-72
38. Antelman SM, Black CA, Rowland NE, et al. Clozapine induces hyperphagia in undeprived rats. Life Sci 1977; 21: 1747-50
39. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3: 1607-19
40. Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 1987; 499: 203-15